A Randomized, Open Labeled, Placebo Controlled, Two-Arm, Parallel Group, Multi-Centric, Oral Clinical Study To Evaluate The Sns-01/16 In Healthy Adult Human Female Volunteers Under Fasting Conditions.

开始日期2017-02-28

申办/合作机构

Cholayil Pvt Ltd.

NCT01435720 / Unknown status临床1/2期

Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.

开始日期2011-09-01

申办/合作机构

Sevion Therapeutics, Inc.

100 项与 SNS-01 相关的临床结果

登录后查看更多信息

100 项与 SNS-01 相关的转化医学

登录后查看更多信息

100 项与 SNS-01 相关的专利（医药）

登录后查看更多信息

项与 SNS-01 相关的文献（医药）

2014-10-01·Nanomedicine (London, England)

siRNA Nanoparticles: The Future of RNAi Therapeutics for Oncology?

作者: Chou, Szu-Ting ; Mixson, A James

siRNA clinical trials: state of the art With the emergence of siRNA-based nanomedicine as a powerful therapeutic strategy for cancers, seven of these therapeutics have now advanced to clinical trials. Carriers of siRNA therapeutics include transferrin-modified cyclodextrin (CALAA-01, Arrowhead Research Corporation, CA, USA), in vivo jetPEI (SNS01-T; Sevion Technologies, NJ, USA), cationic liposomes (ALN-VSP02, Alnylam Pharmaceuticals, MA, USA; TKM080301, Tekmira Pharmaceuticals, Burnaby, Canada; Atu027, Silence Therapeutics, London, UK; and DCRMYC, Dicerna Pharmaceuticals, Watertown, MA, USA) and neutral liposomes (siRNA–EphA2–1,2-dioleoyl-sn-glycero3-phosphocholine [DOPC], MD Anderson Cancer Center, TX, USA ). Among those in clinical trials, the cationic lipoplex targeting MYC1a (DCR-MYC) is the only nanoplex that requires the Dicer enzyme in order to obtain functional siRNA. In 2008, the transferrin-modified cyclodextrin polyplex (CALAA-01) was the first siRNA nanoparticle to be approved for cancer clinical trials. In a preclinical mouse study, a single dose of the cyclodextrin nanoplex targeting luciferase mRNA reduced its activity by 80% [1]. More importantly, melanoma patients receiving CALAA-01 in a Phase I clinical trial showed a 50–80% reduction in the RRM2 mRNA compared with mRNA from untreated tumor tissues [2]. Although this study showed promise, the development of CALAA-01 has been delayed and no results have been reported. SNS01-T is a polyethyleneimine (PEI)based (in vivo JetPEI) nanoparticle containing siRNAs targeting EIF5A and decoy plasmids expressing nonhypusinable eIF5A mutants for treatment of multiple myeloma and non-Hodgkin’s B-cell lymphoma [3]. Francis and colleagues have shown that SNS01-T enhances the antitumor efficacy of lenalidomide and bortezomib in a xenograft model [3]. An open-label, Phase I/II doseescalation study that includes 15 patients is currently underway. Sevion technologies, the manufacturer of SNS01-T, has reported no dose-limiting toxicities in four patients at a dose of 0.2 mg/kg of the nanoparticle. Cationic lipid nanoparticles (LNPs) have effectively downregulated oncogenes in malignant hepatomas (CDH16, PLK1, VEGF and MYC1a) and prostate tumors (PKN3) [4]. While LNPs have a circulation half-life that is longer than 18 h [5], most lipoplexes are ultimately internalized by the liver and spleen. Although the accumulation of lipoplexes may lead to tissue toxicity in these organs at higher dosages, they appear to be well-tolerated by humans at defined dosages. In Phase I clinical trials, the maximum tolerated doses were 0.336, 0.75 and 1.25 mg/kg for Atu027, TKM080301 and ALN-VSP02, respectively. As a result, LNPs targeting PKN3 (Atu027) and PLK1 (TKM080301) have been advanced to Phase II trials. Neutral DOPC liposomes have been used to target ovarian cancers (EPHA2, PTK2, and IL8) and melanoma (thrombin receptor) [6]. While siRNA–EphA2–DOPC inhibited tumor growth by approximately siRNA nanoparticles: the future of RNAi therapeutics for oncology?

2014-09-01·Molecular therapy : the journal of the American Society of Gene Therapy1区 · 医学

SNS01-T Modulation of eIF5A Inhibits B-cell Cancer Progression and Synergizes With Bortezomib and Lenalidomide

1区 · 医学

Article

作者: Tang, Terence ; Zheng, Qifa ; Dondero, Richard ; Liu, Zhongda ; Francis, Sarah M ; Thompson, John E ; Taylor, Catherine A

The high rates of recurrence and low median survival in many B-cell cancers highlight a need for new targeted therapeutic modalities. In dividing cells, eukaryotic translation initiation factor 5A (eIF5A) is hypusinated and involved in regulation of protein synthesis and proliferation, whereas the non-hypusinated form of eIF5A is a potent inducer of cell death in malignant cells. Here, we demonstrate the potential of modulating eIF5A expression as a novel approach to treating B-cell cancers. SNS01-T is a nonviral polyethylenimine-based nanoparticle, designed to induce apoptosis selectively in B-cell cancers by small interfering RNA-mediated suppression of hypusinated eIF5A and plasmid-based overexpression of a non-hypusinable eIF5A mutant. In this study, we show that SNS01-T is preferentially taken up by malignant B cells, inhibits tumor growth in multiple animal models of B-cell cancers without damaging normal tissues, and synergizes with the current therapies bortezomib and lenalidomide to inhibit tumor progression. The results collectively demonstrate the potential of SNS01-T as a novel therapeutic for treatment of a diverse range of B-cell malignancies.

2014-01-01·Molecular therapy. Nucleic acids2区 · 医学

From Protein Synthesis to Molecular Biology: The Appealing Tale of eIF-5A

2区 · 医学

ArticleOA

作者: Caraglia, Michele ; Porcelli, Marina ; Alaia, Concetta

A review.Posttranslational hypusine modification of lysine 50 of the eukaryotic initiation factor 5A (eIF-5A) is associated with the function of this factor in cell proliferation and differentiation and is involved in tumor formation, progression and maintenance (for a review see reference 1).In a Mol. Therapy Issue, Francis et al. report that knock down of hypusine formation in eIF-5A through RNA interference strategies is a promising approach for the treatment of B-cell neoplasia².The authors had previously employed this strategy in models of multiple myeloma to abrogate hypusination of eIF-5A by codelivery of an siRNA targeted to the eIF-5A mRNA along with a plasmid encoding a mutated form of eIF-5a that can be not hypusinated.³ The new twist in the follow-up study is that the authors have demonstrated synergistic activity of this strategy when coupled with well-established modalities of treatment of patients affected by lymphoproliferative diseases, suggesting that this approach could translate readily to a clin. setting.Hypusine modification of eIF-5A is involved in regulation of its activity in both protein synthesis and eukaryotic cell growth.Several strategies have been used to inhibit hypusine formation.N1-guanyl-1,7-diaminoheptane (GC7), a nonspecific inhibitor of one of the two enzymes that mediate the hypusination, efficiently inhibits tumor cell proliferation.However, it gives rise to in vivo toxicity owing to its effect upon other enzymes.^4,5 A way to limit the toxicity of anti-cancer agents is to combine them with other nontoxic drugs that exhibit synergistic inhibition of cell proliferation.In this light, the anticancer cytokine interferon α (IFNα) showed synergistic anticancer activity with GC 7 (reference 6) and IFNα-mediated cell growth inhibition was associated with decreased hypusine synthesis and altered eIF-5A function.⁷ However, eIF-5A is expressed as two different isoforms with different functions: eIF5A1, which in its nonhypusinated form induces mitochondria-mediated apoptosis and eIF5A2, which in its nonhypusinated form loses its oncogenic potential.⁸ Interestingly, GC7 also increases the response of bladder cancer cells to doxorubicin, likely due to its ability to antagonize epithelial-mesenchymal transition through inhibition of eIF-5A2 hypusination and function.⁹ On these bases, the hypusination of both isoforms is essential to the oncogenic activity of eIF-5A and a benefit of the strategy used by Francis et al. is that it completely abrogates hypusine formation in eIF-5A without inducing nonspecific side effects.Lymphoproliferative diseases represent an attractive target for this approach since there is an urgent need for new therapeutic strategies in chemo- or immuno-resistant patients.However, a previous report by Scuoppo et al. revealed a tumor suppressor function for hypusinated eIF5A in lymphoproliferative diseases.¹⁰ These contradictory results were observed in an Eμ-Myc overexpression mouse model of lymphomagenesis that is very similar to Burkitt lymphoma, in which the lack of eIF5A hypusination promotes c-Myc-driven tumorigenesis.This is however the only report of tumor suppressor function of eIF-5A and, therefore merits addnl. investigation.As noted above, the same research group demonstrated the activity of SNS01 in models of multiple myeloma.³ This work advances the strategy reported in the previous report by demonstrating synergistic activity with bortezomib and an additive effect when combined with lenalidomide in inhibiting the growth of lymphoproliferative diseases.The use of combinatorial strategies in the treatment of cancer is an important challenge that requires determination of the optimal combination of complementary agents and their sequence of administration.The choice of optimal therapeutic strategy also depends upon the detection of predictive markers of response to therapy.In the case of eIF-5A targeted strategies, predictive biomarkers have yet to be determined and relevant animal studies are strongly warranted.Moreover, Francis et al. employed polyethylenimine (PEI)-based nanoparticles to deliver their nucleic acid therapy to the tumor tissues.PEI promotes self-assembly of nanoparticles so as to protect their contents from serum nucleases and is an efficient system for delivery of nucleic acids in vivo and in humans.However, only certain PEIs can be used for in vivo applications: they must exhibit an overall pos. charge that allows them to bind to the neg. charged heparan sulfate proteoglycans on the cell surface.This can induce different side effects, such as liver necrosis, adhesion of aggregated platelets, shock after systemic injection at higher doses and stimulation of immune system and lung inflammation.¹¹ Delivery strategies can be optimized through the use of second-generation nucleic acid-nanocarriers such as stabilized nucleic acid lipid particles (SNALPs).It has been demonstrated that SNALPs are able to efficiently deliver miRNAs in the treatment of lymphoproliferative diseases and multiple myeloma without signs of toxic side effects.^12,13 SNALPs can also allow the functionalization of their surface with macrophage escaping mols. (such as polyethylene glycol), active targeting moieties (such as transferrin) or cell penetrating peptides.It was recently reported that miRNAs can be suitable tools to inhibit cell growth through the interference with eIF-5A.¹⁴ The advantage of miRNAs as a therapeutic derives from their ability to inhibit multiple intracellular targets and to give rise to pleiotropic interfering functions upon multiple pathways involved in tumorigenesis and cancer cell proliferation.In conclusion, the manuscript by Francis et al. opens an appealing scenario in which a factor traditionally involved in protein synthesis machinery regulation becomes a mol. target for in vivo anti-cancer approaches.The latter are based on both the use of RNA interference techniques and nanotechnol.-based delivery strategies.Based on the results from Francis et al., exploratory clin. trials are strongly warranted and the optimization based on the search for both the optimal weapon and delivery strategy and on the finding of predictive biomarkers is still required (for a summary, see Figure 1).

项与 SNS-01 相关的新闻（医药）

2022-12-08

·BioSpace

Sensei Biotherapeutics Provides Update on Strategic Priorities

- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses - - Continued focus on development of TMAb™ programs; IND submission for lead antibody SNS-101 anticipated in or prior to April 2023 - - Cash runway extended into the second half of 2025 - BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- eSensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced a streamlining and realignment of resources to support its key indications and programs, including its lead antibody, SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb™ (Tumor Microenvironment Activated biologics) platform programs. In connection with this announcement, the Company will close its research site in Boston and reduce its total workforce by approximately 40%. The Company expects that such reduction in operating expenses, including employee-related costs and reduced occupancy costs, will extend Sensei’s estimated cash runway into the second half of 2025. The Company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of SNS-101 and other TMAb programs is conducted, while maintaining a smaller business office in the Boston area. Sensei plans to relocate any ongoing work at its Boston research site to its Rockville, Maryland site. “Our Board of Directors and management team remain focused on ensuring that Sensei is well positioned to execute on our near-term clinical and preclinical milestones. As we continue to progress the development of SNS-101 towards an IND in the coming months, we have made the strategic decision to reduce our early-stage R&D expenses related to certain discovery stage targets to more closely align with our strategic and financial goals,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. “Today’s announcement follows a thoughtful decision-making process, where we ultimately determined that it is in the best interests of the Company to invest our resources where we believe they will have the greatest potential near-term impact. Decisions that impact our people are always extremely difficult, and I would like to express my gratitude to our departing employees for their hard work and service. We are committed to providing support for our impacted colleagues and to helping them identify other opportunities during this transition.” In conjunction with these announcements, Robert Pierce, M.D., Sensei’s Chief R&D Officer, will move to a consulting role as a Science Fellow, effective December 7, 2022, and Edward van der Horst, Ph.D., Sensei’s Senior Vice President, Biologics Discovery & Early Development, has been promoted to Chief Scientific Officer, effective December 7, 2022. Dr. Edward van der Horst, Ph.D. has over 20 years of research and development experience with a strong focus on antibody drug development across diverse target classes in oncology. He has been instrumental in the discovery and development of several clinical-stage therapeutic antibodies, including a first-generation anti-VISTA antibody that is currently in clinical trials as well as the first clinical stage anti-HER3 antibody. During his time at Sensei, Dr. van der Horst has overseen the discovery and early development of SNS-101, Sensei’s conditionally active anti-VISTA antibody, as well as other TMAb platform drug programs. Prior to joining Sensei in 2019, Dr. van der Horst worked at Zenith Epigenetics Ltd., Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and U3 Pharma GmbH (now Daiichi-Sankyo). Dr. van der Horst earned his Ph.D. in biochemistry from the Max-Planck Institute of Biochemistry and conducted his master’s thesis at Max-Planck Institute of Neurobiology. He graduated with an M.S. in chemistry from the Ludwig Maximilian University of Munich. Sensei continues to advance SNS-101 through investigational new drug-enabling studies, and intends to submit an Investigational New Drug application (IND) in or prior to April 2023. The Company has reported differentiated preclinical data demonstrating anti-tumor effects, promising pharmacokinetic properties and a superior cytokine release pro with non-conditional anti-VISTA therapies. While it advances SNS-101 into the clinic in the near-term, Sensei will continue discovery work for its discovery-stage programs targeting VSIG-4 and ENTPDase1, also known as CD39. About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit , and follow the company on Twitter @SenseiBio and LinkedIn. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development of Sensei’s product candidates; the potential safety pro Sensei’s product candidates; the potential benefits of Sensei’s product candidates; the timing of selection of lead product candidates; the timing of an IND submission to the FDA; and Sensei’s belief that its existing cash and cash equivalents will be sufficient to fund its operations at least into the second half of 2025. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies, including the preclinical studies described in this press release, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy pro we anticipate; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 8, 2022 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Michael Biega Senior Director, Investor Relations Sensei Biotherapeutics mbiega@senseibio.com Media Contact: Chris Railey Ten Bridge Communications chris@tenbridgecommunications.com

高管变更

2022-11-22

·BioSpace

Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it has entered into a Sponsored Research Agreement with Washington University in St. Louis, MO, to support development of SNS-101, a conditionally active VISTA-blocking antibody. Research will be conducted in the laboratory of Robert Schreiber, Ph.D., Professor of Pathology & Immunology and Director of the Center for Human Immunology and Immunotherapy Programs, to evaluate the underlying molecular mechanisms that enable SNS-101 to overcome myeloid cell-driven immunosuppression within the tumor microenvironment. “In addition to a deep expertise in immuno-oncology, Dr. Schreiber and his team bring extensive knowledge of the cancer model system planned for these studies as well as access to molecular characterization tools,” said Edward van der Horst, Ph.D., Senior Vice President, Biologics Discovery & Early Development, at Sensei Bio. “Together, we will leverage these attributes to better understand SNS-101’s ability to modulate the tumor microenvironment and potentially achieve tumor rejection where other checkpoint therapies have failed.” Said Dr. Schreiber, “We’re excited to partner with Sensei Bio to further our understanding of how to safely and effectively inhibit VISTA, a promising but challenging target in immuno-oncology. SNS-101 has the potential to unlock VISTA as a powerful immune checkpoint by exploiting the tumor microenvironment using pH-sensitive properties, delivering powerful anti-tumor activity without the negative effects that have thwarted past efforts.” Sensei continues to advance SNS-101 and remains on track to submit an Investigational New Drug application (IND) for SNS-101 in the first half of 2023. The company recently presented preclinical data for the program at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. Disclosure Dr. Schreiber receives compensation as a member of Sensei Biotherapeutics’ Immuno-Oncology Advisory Board, and this financial relationship has been disclosed to Washington University in St. Louis in accordance with institutional policy. About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit , and follow the company on Twitter @SenseiBio and LinkedIn.

免疫疗法

2022-11-21

·GlobeNewswire-Health Care

Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody

- Planned studies aimed at further elucidating the mechanism of SNS-101’s anti-tumor activity -BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it has entered into a Sponsored Research Agreement with Washington University in St. Louis, MO, to support development of SNS-101, a conditionally active VISTA-blocking antibody. Research will be conducted in the laboratory of Robert Schreiber, Ph.D., Professor of Pathology & Immunology and Director of the Center for Human Immunology and Immunotherapy Programs, to evaluate the underlying molecular mechanisms that enable SNS-101 to overcome myeloid cell-driven immunosuppression within the tumor microenvironment. “In addition to a deep expertise in immuno-oncology, Dr. Schreiber and his team bring extensive knowledge of the cancer model system planned for these studies as well as access to molecular characterization tools,” said Edward van der Horst, Ph.D., Senior Vice President, Biologics Discovery & Early Development, at Sensei Bio. “Together, we will leverage these attributes to better understand SNS-101’s ability to modulate the tumor microenvironment and potentially achieve tumor rejection where other checkpoint therapies have failed.” Said Dr. Schreiber, “We’re excited to partner with Sensei Bio to further our understanding of how to safely and effectively inhibit VISTA, a promising but challenging target in immuno-oncology. SNS-101 has the potential to unlock VISTA as a powerful immune checkpoint by exploiting the tumor microenvironment using pH-sensitive properties, delivering powerful anti-tumor activity without the negative effects that have thwarted past efforts.” Sensei continues to advance SNS-101 and remains on track to submit an Investigational New Drug application (IND) for SNS-101 in the first half of 2023. The company recently presented preclinical data for the program at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. DisclosureDr. Schreiber receives compensation as a member of Sensei Biotherapeutics’ Immuno-Oncology Advisory Board, and this financial relationship has been disclosed to Washington University in St. Louis in accordance with institutional policy. About Sensei BiotherapeuticsSensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn. Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development of Sensei’s product candidates and platforms; the potential safety profile of Sensei’s product candidates; the potential benefits of Sensei’s product candidates; and the timing of an IND submission to the FDA. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Annual Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 8, 2022 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact:Michael BiegaSenior Director, Investor RelationsSensei Biotherapeuticsmbiega@senseibio.com Media Contact:Chris RaileyTen Bridge Communicationschris@tenbridgecommunications.com

免疫疗法

100 项与 SNS-01 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性B细胞淋巴瘤	临床2期	美国	Sevion Therapeutics, Inc.	2011-09-01
复发性B细胞淋巴瘤	临床2期	南非	Sevion Therapeutics, Inc.	2011-09-01
复发性弥漫性大B细胞淋巴瘤	临床2期	美国	Sevion Therapeutics, Inc.	2011-09-01
复发性弥漫性大B细胞淋巴瘤	临床2期	南非	Sevion Therapeutics, Inc.	2011-09-01
复发性套细胞淋巴瘤	临床2期	美国	Sevion Therapeutics, Inc.	2011-09-01
复发性套细胞淋巴瘤	临床2期	南非	Sevion Therapeutics, Inc.	2011-09-01
浆细胞白血病	临床2期	美国	Sevion Therapeutics, Inc.	2011-09-01
浆细胞白血病	临床2期	南非	Sevion Therapeutics, Inc.	2011-09-01
复发性多发性骨髓瘤	临床2期	美国	Sevion Therapeutics, Inc.	2011-09-01
复发性多发性骨髓瘤	临床2期	南非	Sevion Therapeutics, Inc.	2011-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASGCT2012	N/A	多发性骨髓瘤 \| 淋巴瘤	-	SNS01-T	積願鏇顧壓願糧願膚廠(製夢膚鏇簾築繭構廠製) = 積鏇觸窪簾選夢遞顧窪繭簾鹽膚構壓蓋憲簾糧 (艱鏇襯壓淵鏇糧繭獵願, 0.75 mg/kg) 更多	-	2012-05-01
				SNS01-T	積願鏇顧壓願糧願膚廠(製夢膚鏇簾築繭構廠製) = 顧願夢齋遞廠憲艱網憲繭簾鹽膚構壓蓋憲簾糧 (艱鏇襯壓淵鏇糧繭獵願 )